![]() ![]() He spent at least a year in litigation attempting to undo a New Jersey Supreme Court injunction so he could satisfy his discriminatory impulses. ![]() Hugin's federal lawsuit sought both to exclude women from joining and to purge current female members. Most damningly, because women had already been admitted as members of Tiger Inn, Mr. Bob Hugin was in his mid-to-late 30s and married when he waged his delusional war to subjugate women and preserve the glory days of male dominance he so fondly enjoyed as an undergrad. ![]() These were the calculated attempts of a grown man. Hugin cannot claim that these were the mere actions of a young, naive student. After his Tiger Inn was forced to accept women in 1991, Hugin went to federal court in hopes of preserving ‘the right to determine our own membership.’ And when his legal efforts to discriminate against women failed again, Hugin expressed disappointment, insisting ‘we had a strong case and a high probability of winning.’ When the New Jersey Supreme Court ended the social club's discriminatory policy and opened the doors to women, he called the decade-long fight for inclusion ‘politically correct fascism.’ But Hugin didn't stop there. It cannot be tolerated by any individual seeking to represent New Jersey. “It is outright appalling that Bob Hugin actively fought against women joining his exclusive, all-male Princeton University eating club while serving as its alumni board President. Thank you for all of your hard work! #TeamHugin /n9daZSuwRM Juno’s shares closed at $52.37 on the NASDAQ yesterday, compared to $46.61 the Friday before the deal was announced on Monday, June 29.Great conversation with our fantastic team of interns this morning. ![]() The companies did not disclose whether Juno will retain manufacturing rights for drugs Celgene markets under the partnership. We think that together, we really can be super-competitive of assets, given the potential for modulating these cells in different ways.” “ If you need a transducer, that is what Juno good at, if the small molecule is relevant or protein, they are some of the things that Celgene is great at. “One of the unique features of this collaboration is that our equity ownership can increase over time and allow Celgene's shareholders to benefit by the broader value creation in Juno,” said Hugin.īarney Cassidy, Juno General Counsel and Secretary, said the collaboration will add value to both companies in deals with third-party partners looking to exploit T-cell tech: “ We do not anticipate any meaningful collaboration related costs to impact our near-term ,” he added. In a conference call, Celgene CEO Bob Hugin told investors the partnership could effect product approvals by 2020. Juno will have the option to partner with Celgene on certain of Celgene’s candidates that target T-cells, and receive 30% of the profits. Juno also retains R&D and commercialistion rights for all its drug candidates in North America. Juno’s B-Cell Maturation Antigen (BCMA) not part of the collaboration. Outside of CD19 and CD22, Celgene can pick two of Juno’s pipelines for share expenses and profits with Juno for all markets, except China. The companies will co-promote other Juno programmes worldwide.Ĭelgene will make an initial payment of around $1bn, made up of 9.1m Juno shares and $150m cash.Ĭelgene has the option to commercialise Juno’s oncology and cell therapy auto-immune product candidates, including CD19- and CD22-directed CAR-T product candidates. The joint venture aims to bring Juno’s T-cell tech to market outside North America, including Chimeric Antigen Receptor Technology (CAR-T) and T cell Receptor (TCR) platforms. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |